Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation

25 Feb 2011

Abstract excerpt

Bannayan-Riley-Ruvacalba syndrome (BRRS) belongs to the PTEN hamartoma tumor syndromes and is characterized by a high risk of malignancy in early adulthood added to local destructive effects of hamartomas in childhood. There is no standard treatment for this condition and patients are usually offered symptomatic surgical relief. Rapamycin has been reported to be effective in the management of other conditions...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PI3K/AKT/mTOR signaling in cancer
Share to Tuberous Sclerosis Complex Research
Share to Vascular Tumors and Angiosarcomas

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21360661
DOI: 10.1002/pbc.23098

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutationPMID 21360661Read ↗

Rapamycin treatment for a child with germline PTEN mutationSemantic proximity Read ↗

PTEN hamartoma tumor syndrome in childhood and adolescence—a comprehensive review and presentation of the German pediatric guidelineSemantic proximity Read ↗

Airway obstruction caused by PTEN hamartoma (Bannayan-Riley-Ruvalcaba) syndrome.Semantic proximity Read ↗

Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.Semantic proximity Read ↗

PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic DiseasesSemantic proximity Read ↗

mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disordersSemantic proximity Read ↗

PTEN hamartoma tumor syndromes in childhood: description of two cases and a proposal for follow-up protocol.Semantic proximity Read ↗

Perfect match: mTOR inhibitors and tuberous sclerosis complexSemantic proximity Read ↗

Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis ComplexSemantic proximity Read ↗

[Bannayan-Riley-Ruvalcaba syndrome and juvenile polyposis in a two-year-old girl].Semantic proximity Read ↗

The spectrum and evolution of phenotypic findings in <i>PTEN</i> mutation positive cases of Bannayan-Riley-Ruvalcaba syndromeSemantic proximity Read ↗

Severe lupus nephritis in a young adult with PTEN hamartoma tumour syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.